Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athenex Inc ATNXQ

Healthcare Biotechnology
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is... see more

Recent & Breaking News (GREY:ATNXQ)

Athenex Pharmaceutical Division, an Athenex, Inc. Company, Launches Levothyroxine Sodium for Injection

GlobeNewswire December 26, 2018

CORRECTION: Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer

GlobeNewswire December 11, 2018

Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer

GlobeNewswire December 11, 2018

Recent Analysis Shows Athenex, National CineMedia, Macy's, Manulife Financial, CBS, and Strategic Education Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire December 6, 2018

Athenex to Host an R&D Day on December 17 in New York

GlobeNewswire December 6, 2018

Athenex Announces Licensing Agreement with PharmaEssentia for Rights to Oradoxel (Oral Docetaxel) in Certain Asian Territories

GlobeNewswire November 29, 2018

Athenex Announces Initiation of a Phase I/II Clinical Study of Oraxol in Combination with Anti-PD1

GlobeNewswire November 26, 2018

Athenex, Inc. Announces Third Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire November 14, 2018

Athenex, Inc. to Report Third Quarter Earnings Results on November 14, 2018

GlobeNewswire November 1, 2018

Athenex Announces FDA Allowance of Investigational New Drug Application of Eribulin ORA to Begin Clinical Trials

GlobeNewswire October 29, 2018

Recent Analysis Shows Prologis, Delek Logistics Partners, Fabrinet, New York Mortgage Trust, Petroleo Brasileiro S.A.- Petrobras, and Athenex Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire October 26, 2018

ESMO 2018: Athenex Presented Encouraging Clinical Trial Efficacy and Safety Results of Oraxol in the Treatment of Metastatic Breast Cancer

GlobeNewswire October 22, 2018

Athenex to Present Positive Data of Oraxol Clinical Trial in Breast Cancer at the ESMO 2018 Congress

GlobeNewswire October 16, 2018

Athenex and Xiangxue Life Sciences Announce Preliminary Results of Patients Receiving T-Cell Receptor Affinity Enhancing Specific T-Cell Therapy (TAEST) Showed Encouraging Positive Clinical Signals

GlobeNewswire October 15, 2018

Report: Developing Opportunities within RLJ Lodging Trust, Solar Capital, Athenex, Bonanza Creek Energy, Mueller Industries, and Corporate Office Properties Trust — Future Expectations, Projections Moving into 2018

GlobeNewswire September 25, 2018

Athenex and its Collaborative Partner, Hanmi Pharmaceutical, Announce Strategic Realignment of their Joint Projects

GlobeNewswire September 12, 2018

Athenex Announces Positive Recommendation by the Drug Safety Monitoring Board Upon the Second Interim Analysis and to Continue the Oraxol Phase III Program

GlobeNewswire September 5, 2018

Athenex Appoints Randoll Sze as Chief Financial Officer

GlobeNewswire August 20, 2018

Athenex, Inc. Announces Second Quarter 2018 Results and Provides Corporate Update

GlobeNewswire August 14, 2018

Athenex Pharma Solutions, an Athenex, Inc. Company, Launches Compounded Vasopressin Injection in Ready-to-Use Premix IV Bags

GlobeNewswire August 13, 2018